Sort
48,018 grants matching “immunotherapy”
Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy
$521,454Zihai Li · Ohio State University · R01 · FY2024 · CA
Immunomodulating Ruthenium Metal Complexes for Melanoma PhotodynamicTherapy
$521,452Sherri McFarland · University Of Texas Arlington · R01 · FY2021 · CA
Single Cell Genome-Wide Myeloid Response Profiling in Immunotherapy
$521,401Allon Moshe Klein · Harvard Medical School · R01 · FY2022 · CA
Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma
$521,277Isabel Kurth · Rgenix, Inc. · R44 · FY2017 · CA
Project 3
$521,211Branden S Moriarity · University Of Minnesota · P01 · FY2024 · CA
The CD226 and TIGIT Costimulatory Axis in Type 1 Diabetes
$521,191Todd Michael Brusko · University Of Florida · R01 · FY2020 · DK
Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.
$521,188Christopher Austin Klebanoff · Sloan-Kettering Inst Can Research · R37 · FY2025 · CA
Vaccine and Drug Combination Therapy for Human Cancers
$521,180James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Vaccine and radiation for the therapy of human cancers
$521,180James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Project 2: A Novel Cellular Tumor Vaccine Strategy for Glioblastoma
$521,167Michael D Gunn · Duke University · P01 · FY2020 · CA
Immunotherapeutic Nanoparticle Delivery to Melanoma With MR-Guided Focused Ultrasound
$521,056Richard J Price · University Of Virginia · R01 · FY2016 · CA
Project 1: Evaluating stem-like T cells and improving efficacy of checkpoint inhibitors in NSCLC
$521,029Rafi Ahmed · Emory University · P50 · FY2019 · CA
Improving the translational value of head and neck cancer patient-in-mouse models
$520,953Randall J Kimple · University Of Wisconsin-Madison · R37 · FY2021 · CA
Defining post-transcriptional mechanisms that control CD8 T cell longevity, proliferation and differentiation
$520,929Leonid Pobezinskiy · University Of Massachusetts Amherst · R01 · FY2020 · AI
Understanding how T cell intrinsic androgen receptor activity influences cell differentiation and dysfunction
$520,926Amy E Moran · Oregon Health & Science University · R37 · FY2024 · CA
Genetic Approaches to Optimize CAR T cells for Glioblastoma Therapy
$520,925Irina V Balyasnikova · Northwestern University At Chicago · R01 · FY2022 · NS
Promoting immunity against acute myeloid leukemia through Fc effector-optimized antibody inhibitory of MICA/B shedding
$520,895Lucas Ferrari De Andrade · Icahn School Of Medicine At Mount Sinai · R37 · FY2025 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$520,857Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2021 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$520,857Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2019 · CA
Therapeutic Targeting of Immune Evasion from the MICA - NKG2D Pathway
$520,857Kai W Wucherpfennig · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer
$520,837Cloud Peter Paweletz · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Non-invasive Quantification of Dose-Exposure-Response of PD-L1 Therapeutics at the Tumor
$520,780Sridhar Nimmagadda · Johns Hopkins University · R01 · FY2018 · CA
Localized immunotherapy using alum-binding therapeutics
$520,695Darrell J Irvine · Massachusetts Institute Of Technology · R01 · FY2022 · EB
Tumor microenvironment: Impact on T cell tumor-targeting, activation and survival
$520,680Ronald G Blasberg · Sloan-Kettering Inst Can Research · R01 · FY2012 · CA
Immunotherapy to Counteract Lethal Doses of Carfentanil
$520,662Kim D Janda · Scripps Research Institute, The · U01 · FY2019 · DA